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Melanomas are highly lethal skin tumours that are frequently
treated by surgical resection. However, the efficacy of such
procedures is often limited by tumour recurrence and
metastasis. Caveolin-1 (CAV1) has been attributed roles as
a tumour suppressor, although in late-stage tumours, its
presence is associated with enhanced metastasis. The
expression of this protein in human melanoma development
and particularly how the presence of CAV1 affects
metastasis after surgery has not been defined. CAV1
expression in human melanocytes and melanomas
increases with disease progression and is highest in
metastatic melanomas. The effect of increased CAV1
expression can then be evaluated using B16F10 murine
melanoma cells injected into syngenic immunocompetent
C57BL/6 mice or human A375 melanoma cells injected
into immunodeficient B6Rag1–/– mice. Augmented
CAV1 expression suppresses tumour formation upon a
subcutaneous injection, but enhances lung metastasis of
cells injected into the tail vein in both models. A procedure
was initially developed using B16F10 melanoma cells in
C57BL/6 mice to mimic better the situation in patients
undergoing surgery. Subcutaneous tumours of a defined
size were removed surgically and local tumour recurrence
and lung metastasis were evaluated after another 14 days.
In this postsurgery setting, CAV1 presence in B16F10
melanomas favoured metastasis to the lung, although
tumour suppression at the initial site was still evident.
Similar results were obtained when evaluating A375 cells
in B6Rag1– / – mice. These results implicate CAV1
expression in melanomas as a marker of poor prognosis
for patients undergoing surgery as CAV1 expression
promotes experimental lung metastasis in two different
preclinical models. Melanoma Res 24:108–119 c 2014
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Introduction
Cancer is a leading cause of death worldwide, whereby the
large majority of patients succumb as a consequence of
metastasis to secondary sites rather than tumour growth at
the initial site. Skin cancer is currently considered the third
most common human malignancy and its incidence is
increasing worldwide at an alarming rate because of
environmental and behavioural changes. Within this group
of cancers, melanomas are the most dangerous form and
account for the majority of skin cancer-related deaths. As for
other cancers, metastasis is considered the major threat to
patient survival. Identification of relevant prognostic mo-
lecular markers in this context is therefore of great interest.
Caveolins are a family of proteins that are generally impli-
cated in the formation of plasma membrane-associated
structures called caveolae, in cholesterol transport and in
the control of a large variety of cell signalling events. To date,
three isoforms have been identified in mammals: caveolin-1
(CAV1), CAV2 and CAV3. In the context of cancer, CAV1 is
the most studied isoform and a considerable amount of data
now suggests that this protein plays a dual role in this com-
plex process [1–4]. For melanomas, relatively little is known
about the role of CAV1. Some initial reports implicated the
protein more as a tumour suppressor in melanoma lines. For
instance, CAV1 was suggested to function as a tumour
suppressor in melanoma cells by disrupting GD3-mediated
signalling events [5]. More recently, exosomes containing
CAV1 were detected in the serum of melanoma patients and
associated with a poor prognosis because of their immune
suppressive effects [6]. Alternatively, knocking down CAV1
expression in a melanoma line that has elevated levels
reduced proliferation and tumourigenicity [7]. Despite such
evidence, another recent report indicates that CAV1 blocks
metastasis of malignant melanomas in a murine model [8].
Thus, the role of CAV1 in melanoma and particularly the
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possible consequences of CAV1 expression for patient
survival postintervention remain unclear.
Here, we first evaluated the expression of CAV1 in human
melanocytes and melanomas and observed a gradual increase
in the expression of this protein with progression of disease.
We then determined how the augmented presence of CAV1
introduced into human A375 or murine B16F10 melanoma
cells promoted metastasis to different organs depending on
the model. Given the importance of surgical procedures as an
initial line of defence to eradicate melanomas, we used
human A375 cells in immunodeficient B6Rag1– / – mice and
mouse B16F10 cells in syngenic C57BL6 mice to evaluate
how CAV1 affected surgery outcome. Following initial sub-
cutaneous tumour growth to a defined size/volume in the
two mouse models, the tumours were removed by standard
surgical procedures applied in humans. After another defined
period, animals were killed and tumour formation at the
initial site as well as metastasis to the lung were evaluated.
Using this model, we provide direct experimental evidence
that CAV1 expression in melanomas before surgery favours
metastasis and hence represents a negative prognostic marker
for the outcome of surgical procedures.
Methods
Polyclonal anti-CAV1 antibodies were from Transduction
Laboratories (Lexington, Kentucky, USA). Antiactin anti-
bodies were from R&D Systems (Minneapolis, Minnesota,
USA) and Sigma (St Louis, Missouri, USA), respectively.
Goat anti-rabbit immunoglobulin-G and goat anti-mouse
immunoglobulin-G antibodies coupled to horseradish per-
oxidase were obtained from BioRad Laboratories (Hercules,
California, USA) and Sigma, respectively. Isopropyl b-D-1-
thiogalactopyranoside (IPTG) was from Sigma. The EZ-
ECL chemiluminescent substrate was from Biological
Industries (Kibbutz Beit Haemek, Israel). Hygromycin
was from Calbiochem, La Jolla, California, USA. Cell media
and antibiotics were from Gibco-BRL, Scotland, UK. Foetal
bovine serum (FBS) was from Hyclone, Logan, Utah, USA.
All other reagents used for western blots or cell culture were
from Sigma or of the highest grade available.
Western blotting
Protein extracts were separated by SDS-PAGE on 12%
minigels (BioRad), loading 50mg total protein. Blots were
blocked with 5% milk in 0.1% Tween-PBS and probed with
antiactin (1 : 5000) or anti-CAV1 (1 : 3000) antibodies.
Bound antibodies were detected with horseradish perox-
idase-conjugated secondary antibodies. CAV1 protein levels
were quantified by scanning densitometry, standardized to
actin levels in the same samples and comparing in each set
with normal human melanocytes assigned a reference value
of 1 (mean±SD, from three different experiments).
Animals
Pathogen-free immunodeficient B6Rag1 – / – (B6.129S7
Rag1< tm1Mom> /J) mice were from Jackson Labora-
tories (Bar Harbor, Maine, USA), whereas C57BL/6 mice
were obtained from the ISP (Santiago, Chile). Animals
were kept in the animal facility of the Andes Biotechnolo-
gies and Immunology Laboratory, Universidad de Chile,
respectively. Mice between 8 and 12 weeks of age were
used for experiments (approved by the local bioethics
committee, CBA0271CMUCH).
Cells and culture condition
Human melanoma lines were obtained from Dr Meenhard
Herlyn, Wistar Institute, Pennsylvania, USA (WM lines),
and from Dr I. Hart, G. Moore and P. Parsons, and were
grown in RPMI1640 medium with 10% FBS, 2mmol/l L-
glutamine, 100U/ml penicillin, 100 mg/ml streptomycin
and 10% CO2, with the exception of WM1650, which
were grown in the same medium with 200 nmol/l
tetradecanoyl phorbol acetate and 100 pmol/l cholera
toxin. Hermes 3A immortal human melanocytes (infor-
mation concerning these cell lines is available at
http://www.sgul.ac.uk/depts/anatomy/pages/WTFGCB.htm), and
NOHM-4 normal neonatal human melanocytes, were
obtained from Cascade Biologics, now MSD Biologics
(Billingham, UK).
B16F10 (mock), B16F10 (cav-1), A375 (mock) and A375
(cav-1) cells induced or not with IPTG have been
described [4,9]. All cells were cultured in RPMI
supplemented with 10% FBS, 2mmol/l glutamine and
antibiotics (100U/ml penicillin and 100 mg/ml strepto-
mycin) at 371C, 5% CO2. The NhuM melanocyte cell
line (ATCC Pcs-200-012) and the HEKn keratonocyte line
(HEKn-APF Cascade Biologicals C-020-5C) were cul-
tured in the Dermal Cell Basal Medium Kit (ATCC
Pcs200-030; ATCC, Manassas, Virginia, USA) and Kera-
tinocyteSFM (Gibco 10725018 suppl37000-015; Gibco,
Carlsbad, California, USA), respectively.
Immunohistochemistry
The tissue array used in this study, referred to as
MEL961, includes 48 tissue sections of melanomas at
different stages and also normal tissue (http://www.panto
mics.com/TissueArrays/Skin/Human/MEL961.aspx). Tissue ar-
rays were deparaffinated and hydrated following standard
procedures. Antigenicity was recovered treating samples
with Retrieval solution (S1699; DACO, Rune Linding,
Denmark) at 1001C for 20min. After washing, tissue
arrays were blocked with goat serum 2% (diluted in PBS
1 ) for 30min and incubated with the primary antibody
(1 : 100 in goat serum 2%) overnight. Samples were then
washed 3 for 5min with PBS 1 . First, antibodies were
subsequently detected using the UltraVision LP Detec-
tion System-HRP Polymer & DAB Plus Chromogen
(TL-015-HD; Thermo Scientific, West Palm Beach,
Florida, USA) following the instructions provided by
the manufacturer. Finally, samples were counterstained
with haematoxylin, dehydrated and mounted in perma-
nent medium Entellan (Merck, Darmstadt, Germany).
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Tumour growth assays
A375 (2 000 000 or 5 000 000) or B16F10 (300 000)
cells were injected subcutaneously into the flanks of
B6Rag1 – / – or C57BL/6 mice, respectively. The appear-
ance of tumours was monitored by palpitation (tumor
volume=width2 length p/6). In initial experiments
using B16F10 cells, mice were injected simultaneously in
the left and right flank with different cell lines [B16F10
(mock) and B16F10 (cav-1)] (Fig. 3). However, because
of the considerable differences in tumour growth rates,
mice were injected with only one cell line for the
subsequent surgery experiments (Figs 4 and 5).
Metastasis assays
Immunodeficient B6Rag1 – / – mice injected intraven-
ously with 5 000 000 A375 (mock) or A375 (cav-1) cells
were killed day 21 after injection; the liver and lungs were
fixed in Fekete’s solution. Metastasis was evaluated by
analysing photographs. Because A375 are nonpigmented
cells, tumour nodules apparent at the surface of liver and
lung were determined (Fig. 2e and f). Animals injected
intravenously with 200 000 B16F10 cells were killed day
21 after injection and lungs were fixed in Fekete’s
solution. Black tissue, corresponding to lung metastases,
was separated from the rest of the lung and weighed.
Metastasis is expressed as black tissue mass/total lung
mass (%). In these experiments, mice were evaluated
according to established criteria [10–12].
Surgery model
C57BL6 mice were injected subcutaneously with B16F10
(mock) or B16F10 (cav-1) (3 105/100ml in NaCl 0.9%),
Fig. 1
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CAV1 levels in human melanocytes and melanoma cell lines. Human melanocytes and melanoma cell lines were grown in 100mm plates (see the Methods
section). At 70% confluence, cells were harvested, extracts were prepared and proteins were separated by SDS-PAGE in 12% minigels (50mg total
protein per lane), transferred to nitrocellulose and analysed by western blotting with anti-CAV1 and antiactin antibodies. CAV1 protein levels were
quantified by densitometric analysis. Numerical data were normalized to actin and averaged from three independent experiments (mean±SD, *P<0.05).
(a, b) Representative blots are shown for the following: Hermes 3A and NOHM-4 (normal human melanocytes, M); MM200 (primary melanoma, PM),WM35
and WM1650 (radial growth phase, RGP); ME1402, Me10538, WM1341, WM98-1 and WM239A (vertical growth phase, VGP) and WM1158,
COLO793 and DX3 cells (metastatic, Mts). Human fibroblasts were included as a positive control for CAV1 expression. (c) Relative CAV1 expression levels
are graphed for the different human melanoma preparations. Statistically significant differences are indicated (*P<0.05). (d) Immunodetection of CAV1 in
human samples using tissue arrays (normal tissue sample A04; MEL961 Pantomics). Individual melanocytes within the keratinocyte layer are highlighted
(red arrows). Note that CAV1 was essentially undetectable in normal melanocytes when compared with keratinocytes (100 ). Western blot insert: NhuM
cells (melanocyte cell line) and HEKn (keratinocyte cell line) were compared. Note that CAV1 levels were at least 10-fold higher in HEKn cells. (e) CAV1
expression was determined as described for different stages of melanoma development. In the order of increasing invasiveness, representative samples of
RGP, VGP and higher metastatic state are shown (E06, F11, H12; respectively; MEL961 Pantomics). CAV1, caveolin-1.
110 Melanoma Research 2014, Vol 24 No 2
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
(Figs 3 and 5) using two different procedures: (a) animals
were injected with tumour cells on different days to allow
operating on equal-sized tumours the same day. Mice
were injected on day 0 with B16F10 (cav-1) and on day 4
with B16F10 (mock) cells (Fig. 5a). (b) All animals were
injected the same day with the B16F10 (mock) and
B16F10 (cav-1) cells and tumours were surgically
removed as they reached 1500–1800mm3. A comparison
of tumour volumes for all experiments showed no
significant differences between the animals injected with
B16F10 (mock) and B16F10 (cav-1) cells (Fig. 4c).
Tumours were removed using standard techniques
applied in humans (complete and en-bloc resection).
When tumour margins were visually compromised,
surgical margins were widened so that no tumour mass
was macroscopically visible. The open surgery wound was
washed with saline solution and then sutured with silk
3.0 threads. Mice were treated with palliative medication.
All the remaining mice were eventually killed on day 14
after surgery. Lung metastasis is expressed as black tissue
mass/total lung mass (%, Fig. 6). In the immunodeficient
surgical model, B6Rag1 – / – mice were injected subcuta-
neously with 5 000 000 A375 (mock) or A375 (cav-1) cells
and tumours were surgically removed when they reached
850–1100mm3 (Fig. 6).
Extumour cells
Developing tumours (Fig. 3) were surgically removed
when they reached volumes of 1500–1800mm3. Gelat-
inous material from the tumour interior was trypsinized
for 15min at 371C, and then mechanically teased apart
with tweezers and suspended in medium. The cells
(mainly melanomas) were left to adhere to the plate for
6 h. Then, fresh culture was added. All cells were
cultured in RPMI supplemented with 10% FBS,
2mmol/l glutamine and antibiotics at 371C, 5% CO2.
Upon reaching 90% confluence, cells were trypsinized
and replated again. Cells obtained after two passages in
culture are referred to as B16F10 extumour cells.
Statistical analysis
The results of Western blot experiments were compared
statistically using the Kruskal–Wallis test. In-vivo experi-
ments were compared using unpaired t-tests. A value of
P less than 0.05 was considered significant.
Results
Increased CAV1 expression with melanoma malignancy
In the normal skin, melanocytes are closely associated
with basal keratinocytes. With the onset of melanocytic
naevus formation, increased numbers of the morphologic-
ally atypical melanocytes are detected in the basal layer.
In the radial growth phase (RGP), pigmented cells spread
out essentially horizontally and can also lose contact with
the keratinocytes. Then, in the vertical growth phase
(VGP), the number of pigmented cells increases con-
siderably and foci penetrate the dermis and may enter
subcutaneous layers. Finally, metastatic cells (Mts)
detach from the initial site and migrate to nearby or
distant organs [13]. Here, we compared by western blot
analysis CAV1 levels in human melanocytes with those of
primary malignant RGP, VGP and Mts cells and detected
a highly significant increase in CAV1 expression with
increasing progression of disease (Fig. 1a). This observa-
tion was corroborated in an analysis comparing additional
VGP and Mts cell lines. In this case, fibroblasts were
included as a positive control for CAV1 expression. For
some VGP and Mts lines, CAV1 expression was as high as
in the fibroblast controls (Fig. 1b). All numerical data
shown in Fig. 1a and b were then compared graphically
and highly significant increases compared with melano-
cyte expression levels (reference value 1) were obtained
for VGP as well as Mts lines (Fig. 1c). Taken together,
these results show that progression of melanoma devel-
opment in humans correlates with increased CAV1
expression.
To further corroborate this conclusion, we also analysed
sections of human tissue samples with melanocytes and
melanomas at different stages using tissue arrays. As
expected on the basis of the aforementioned observa-
tions, the intensity of CAV1 staining increased with
progression of the disease. For melanocytes in normal
tissue, low levels of CAV1 were detected. Specifically,
this is apparent from the comparison of CAV1 staining in
keratinocytes (high) versus melanocytes (low) in normal
tissue samples (Fig. 1d). Western blot analysis indicated
that CAV1 expression in keratinocytes was at least 10-fold
higher than in melanocytes (Fig. 1d, western blot insert).
As predicted on the basis of data shown in Fig. 1c, this
analysis using tissue arrays of samples from human
patients confirmed that CAV1 expression increased as
disease progressed through RGP to VGP and finally fully
blown metastasis.
CAV1 overexpression in A375 human melanomas
suppressed tumour formation and promoted
metastasis in immunodeficient mice
A375 cells were stably transfected with either an empty
vector (pLacIOP) or vector encoding CAV1 (pLacIOP-
cav-1) to generate A375 (mock) and A375 (cav-1) cells,
respectively. In A375 (cav-1) cells, CAV1 levels were
significantly enhanced in the presence of IPTG used to
induce expression (Fig. 2d). A time-course experiment
showed that subcutaneous tumour formation was delayed
for A375 (cav-1) cells (Fig. 2b). At day 38 after injection,
tumour volumes were 268±232 and 1596±247mm3 for
A375 (cav-1) and A375 (mock), respectively (Fig. 2c). Of
note, analysis of animal behaviour day 18 after injection,
according to the criteria established by Morton[12],
yielded a score of 13, indicative of degenerated general
health status and mobility for mice injected with A375
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presence of 1mmol/l IPTG. Immunodeficient B6Rag1– / – mice were injected in the right flank with A375 (cav-1) or A375 (mock) cells (2.5106).
(a) Schematic subcutaneous tumour formation. (b) Time course of tumour formation in B6Rag1– / – mice; black arrow corresponds to day 38.
(c) Tumour volumes measured (day 38) for a total of five mice are shown. For CAV1-expressing cells and mock-transfected controls, tumour volumes
were 268±232 and 1596±247mm3, respectively (mean±SD). (d) Cell extracts from A375, A375 (mock) and A375 (cav-1) cells were analysed by
western blotting with anti-CAV1 and antiactin antibodies. A representative western blot is shown. CAV1 protein levels observed in several
experiments were quantified by scanning densitometry and normalized to actin (mean±SD, n=3; *P<0.05). A375 (mock) and A375 (cav-1) cells
were injected intravenously (5106). Liver and lung tumour metastases were evaluated after 21 days. (e, f) Representative photographs of the liver
(e) and lung (f) showing metastases by A375 (mock) and A375 (cav-1) cells (circles highlight tumours). (g, h) Quantification of total liver and lung
mass evaluated 21 days after mice were injected with either A375 (mock) or A375 (cav-1) cells: liver 1.44±0.1 g compared with 2.73±0.4 g and
lung 0.22±0.02g compared with 0.32±0.02g, respectively (*P<0.05). CAV1, caveolin-1; IPTG, isopropyl b-D-1-thiogalactopyranoside.
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(cav-1) cells, whereas this was not the case for A375
(mock) cells (data not shown). Alternatively, when the
same cells were injected intravenously, lung (Fig. 2e) and
liver (Fig. 2f) metastasis was noticeably enhanced for
A375 (cav-1) cells, whereas this was not the case for A375
(mock) cells. On average, for animals injected with A375
(cav-1) cells, the total liver mass increased at least 1.8-
fold compared with the control animals (Fig. 2g), whereas
increments in lung volume were less pronounced (1.5-
fold; Fig. 2h).
Thus, although CAV1 shows characteristics typical of a
tumour suppressor in subcutaneous tumour formation
assays using human melanomas, these beneficial traits
appear to be lost once cells reach the blood stream, as
may occur unintentionally following surgery.
Effect of CAV1 expression on B16F10 behaviour
in tumour formation and metastasis assays
To corroborate these findings, B16F10 murine melanoma
cells were stably transfected with either an empty vector
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(pLacIOP) or vector encoding CAV1 (pLacIOPcav-1) to
generate B16F10 (mock) and B16F10 (cav-1) cells,
respectively. The advantage of this model for the subse-
quent surgery experiments is that the tumour borders are
better defined; metastasis occurs almost exclusively to the
lung, facilitating quantification, and fully immunocompetent
mice are used for the assays. In B16F10 (cav-1) cells, CAV1
expression was significantly enhanced both in the absence
and in the presence of IPTG used to induce expression
(Fig. 5). These cells were then evaluated in syngenic
C57BL/6 mice for their tumour-forming ability (Fig. 3).
Consistent with a role for CAV1 as a tumour suppressor,
tumour formation of B16F10 (cav-1) cells was delayed
compared with B16F10 (mock) cells at all time points
(data not shown). Numerical analysis of the data at day 15
showed that volumes of tumours formed by B16F10
Fig. 4
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(c) Surgically removed tumours of the same size derived from B16F10 (mock) (c1) and B16F10 (cav-1) cells (c2). (d) An animal immediately after
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tumours at the primary site were removed and volumes were measured. Tumours derived from B16F10 (mock) (f1) and B16F10 (cav-1) (f2) cells are
shown. Note that tumours formed at the initial site after surgery by B16F10 (cav-1) cells were smaller than those obtained with B16F10 (mock) cells.
(g) Lungs of mice killed 14 days after tumour surgery were analysed in animals initially injected subcutaneously with B16F10 (mock) (g1) or B16F10
(cav-1) (g2) cells. Note that lung metastasis was more prevalent for B16F10 (cav-1) cells.
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CAV1 suppressed tumour recurrence and increased lung metastasis 14 days after surgery. (a) Schematic of events in surgery experiments; mice
were injected on different days. Tumours between 1500 and 1800mm3 in size were surgically removed. Animals were monitored after surgery and
reincidence of tumour growth as well as lung metastasis were evaluated after sacrificing the animals 14 days later. (b) Tumours formed after surgery
by B16F10 (cav-1) cells were smaller than those derived from B16F10 (mock) cells: 1280±80 and 2543±94mm3, respectively. (c) Lung metastasis
was significantly elevated for B16F10 (cav-1) compared with B16F10 (mock) cells: 20±5 and 7±2%, respectively. (d) Schematic of events in
surgery experiments using mice injected the same day with B16F10 cells. Tumours between 1500 and 1800mm3 in size were surgically removed.
Reincidence of tumour growth as well as lung metastasis were evaluated after killing the animals 14 days later. (e) Tumours formed after surgery by
B16F10 (cav-1) cells were smaller than those derived from B16F10 (mock) cells: 1200±98 and 2543±94 mm3, respectively. (f) Lung metastasis
was significantly elevated for B16F10 (cav-1) compared with B16F10 (mock) cells: 19±4 and 6±2%, respectively. Statistically significant
differences are indicated (***P<0.001, **P<0.01, *P<0.05). B16F10 (mock) and B16F10 (cav-1) cells were grown 48 h in the absence (–) or
presence (+) of 1mmol/l IPTG. Cell extracts were separated by SDS-PAGE and analysed by western blotting with anti-CAV1 and antiactin
antibodies. Results from a representative western blot are shown. CAV1 protein levels quantified by scanning densitometry and normalized to actin
(mean±SD, n=3; *P<0.05) are shown before injection of cells into animals (g). Tumours generated by B16F10 (mock) and B16F10 (cav-1) cells
grown to the same final volume (1500–1800 mm3) (Fig. 4c1, c2) or grown to different volumes and excised the same day (Fig. 2b and c) were
analysed for CAV1 protein levels. (h, i) Cells extracted from tumours in Fig. 2b and c were cultured for two passages (B16F10 extumour cells) and
protein extracts were prepared. Statistically significant differences compared with B16F10 (mock) cells are indicated (*P<0.05). CAV1, caveolin-1;
IPTG, isopropyl b-D-1-thiogalactopyranoside.
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(cav-1) cells were significantly lower (Fig. 3a and b). We
then evaluated the metastatic potential of these cells.
Black lung tumour mass because of metastasis was recorded
on day 21 after an intravenous injection (Fig. 3c). The black
tumour tissue was visible and well defined, in the otherwise
white parenchymal lung tissue (Fig. 3d), and metastatic
mass was 8 and 28% of the total lung mass for B16F10
(mock) and B16F10 (cav-1) cells, respectively (Fig. 3e).
Therefore, the presence of CAV1 in melanoma cells that
were introduced directly into the blood stream elevated the
metastatic potential of these cells. Importantly, sponta-
neous metastasis to the lung from subcutaneous tumours
was not observed (data not shown).
Effect of CAV1 presence on B16F10 behaviour in an
immunocompetent postsurgery model
We then sought to develop a mouse model to evaluate how
CAV1 presence in subcutaneous melanoma tumours might
impact on their potential to regenerate tumours at the initial
site as well as to metastasize to the lung. Of the two
available cell/animal models, we chose to continue studying
B16F10 cells in C57BL/6 mice because tumour borders were
better defined and the mice used are immunocompetent, as
is the case for human patients. B16F10 melanoma cells
expressing or not CAV1 were injected subcutaneously and
tumours were allowed to grow to a defined size (Fig. 4a;
1500–1800mm3). Then, the initial tumour was surgically
removed (Fig. 4b and c), the wound was sutured and
subsequent recovery was monitored (Fig. 4d and e). It
should be noted that at the time of surgery, tumours formed
by CAV1-expressing melanoma cells were of essentially the
same size as those formed by B16F10 (mock) cells
(compare Fig. 4c1 and c2).
On day 14 after surgery, animals were killed and tumour
volumes at the initial site were determined. Consistent
again with the notion that CAV1 functions as a tumour
suppressor, tumours formed by B16F10 (cav-1) cells were
smaller in comparison with B16F10 (mock) cells at the
initial site of tumour growth before surgery (compare
Fig. 4f1 and f2, respectively). However, analysis of tumour
metastasis to the lung in the same mice showed an
increase for CAV1-expressing cells in compari-
son with mock cells (Fig. 4g1 and g2, respectively).
Quantification of results from several experiments (Fig. 5a
and d; time line of experiments) confirmed that tumours
formed by CAV1-expressing B16F10 cells remained smaller
at the primary site (Fig. 5b; **P<0.01 and Fig. 5e;
***P<0.001). However, lung metastasis was significantly
elevated after surgery in those mice that had originally been
inoculated subcutaneously with B16F10 (cav-1) cells
(Fig. 5c; *P<0.05 and Fig. 5f; *P<0.05). Thus, in this
animal model for melanoma surgery, we found that CAV1
expression in B16F10 cells generated less tumour mass at
the primary site and yet enhanced metastasis to the lung. Of
note, metastasis to other sites in the body, such as ganglia,
was only detected in a few cases (data not shown).
CAV1 expression in B16F10 extumour melanoma cells
We evaluated CAV1 expression levels in B16F10 (mock)
and B16F10 (cav-1) cells before subcutaneous injection
and after recovery from the primary tumours (Fig. 5g–i).
As indicated previously, basal CAV1 levels were roughly
six-fold higher in B16F10 (cav-1) than B16F10 (mock)
cells and this difference increased by another 3–4 times
in the presence of IPTG (Fig. 5g). When extumour cells
were compared in the same way (Fig. 5h and i),
significantly higher CAV1 levels were always detected
in those cells isolated from B16F10 (cav-1) tumours.
Note that although the basal levels of CAV1 were
elevated in some cases, CAV1 levels were always
higher in B16F10 (cav-1) than B16F10 (mock) extumour
cells from the same mouse. These observations indicate
that elevated CAV1 expression in melanomas is main-
tained throughout the subcutaneous tumour formation
experiment.
Effect of CAV1 presence on A375 behaviour in an
immunodeficient postsurgery model
Although for A375 (cav-1) cells local tumour recurrence
after surgery was not detected, A375 (mock) cells
develop tumours of 1000mm3 volume or more between
50 and 61 days after surgery (Fig. 6b and c). In contrast,
metastasis was noticeably enhanced for A375 (cav-1) cells
(1.2-fold), whereas this was not the case for A375 (mock)
cells (Fig. 6d).
Discussion
The identification of molecular markers in cancer
patients is becoming increasingly important to improve
diagnosis as well as for the development of more refined
treatments and prognosis following intervention. Here,
we show first that CAV1 expression increased as human
melanocytes progressed through the different stages to
metastatic melanomas. Then, the consequences of
elevating CAV1 expression to levels comparable with
those detected in the human melanomas were evaluated
in two animal models of experimental metastasis. In both
cases, elevated CAV1 promoted metastasis. Finally, using
one of these models, CAV1 was shown also to promote
metastasis in a postmelanoma surgery setting. Together,
these studies identified CAV1 as a protein whose
expression increases with human melanoma progression
and as a factor that favours lung metastasis in preclinical
murine postsurgery settings.
After patients are operated (usually complete resection of
the primary tumour), few clues are available, except for
the Breslow index, to indicate how the disease will evolve
in any given individual. This insight would be helpful
because novel therapies are becoming available that hold
promise in treatments following surgical resection of
the initial melanoma tumour [14–16]. However, there
are essentially no reliable markers to indicate which
patients will be cured by surgery alone, which require
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complementary treatment to avoid metastasis and which
will develop metastasis no matter what treatment is used.
In this respect, our results implicate CAV1 expression in
tumour cells at the initial site as a negative prog-
nostic marker for surgery outcome because of the
enhanced metastatic potential of these cells. Whether it
is important for melanoma cells to maintain CAV1
expression elevated once metastasis has occurred is
not clear. The experiments using the mouse melanoma
model suggest that this might be the case because CAV1
levels were elevated in B16F10 (cav-1) extumour cells
(Fig. 5h and i).
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To enhance CAV1 expression in B16F10 cells, the IPTG-
inducible expression vector pLacIOP was used. In the
absence of IPTG, CAV1 expression was six-fold elevated
in B16F10 (cav-1) cells with respect to B16F10 (mock)
cells and the addition of IPTG enhanced expression
another three- to four-fold (Fig. 5g). Here, it should be
noted that the range of increased expression obtained in
this system correlated remarkably well with increments
detected in metastatic melanomas compared with
melanocytes (Fig. 1). For experiments shown (Figs 3
and 5b,c and e–g) cells were cultured according to
standard protocols in the presence of IPTG for 48 h
before injection into mice [17]. Analysis of extumour cells
showed that in the absence of IPTG, elevated CAV1
expression levels were maintained throughout the
experiments (Fig. 5e and f). These observations are
consistent with our previously reported findings analysing
CAV1 expression in HT29 colon cancer cells after tumour
formation [17].
The A375 human melanoma cells have already elevated
CAV1 levels compared with non-Mts (data not shown).
Stable transfection with pLacIOP (cav-1) led to a five-
fold increase in CAV1 expression (Fig. 2d). Although
more modest than the changes observed for B16F10 cells
(Fig. 5d), this increment was sufficient to reduce tumour
formation by these cells, and yet favours metastasis upon
intravenous injection. Thus, also for human melanoma
cells introduced directly into the blood stream, augmen-
ted expression of CAV1 expression favoured metastasis,
in this case not only to the lung but also to the liver.
Molecular traits in CAV1, required for this dramatic
switch in function, remain to be determined.
Our results using mouse B16F10 and human A375
melanoma cells show that augmented CAV1 protein levels
enhance the metastatic potential of these cells. Consistent
with this interpretation, the expression of CAV1 was
increased in human melanomas in tissues and cell lines
compared with melanocytes from patients, as evidenced by
western blotting (Fig. 1a–c) and immunohistochemical
(Fig. 1d and e) analysis. In this context, another recent
publication should be mentioned [18]. According to this
study, CAV1 may be transferred from tumour cells to stromal
cells (through exosomes or direct cell–cell transfer of
membranes). Thus, a possible alternative interpretation is
that our observations reflect a system in which intrinsic
CAV1 levels in tumour cells may be transferred to stromal
cell populations and condition a niche for metastatic
melanoma cells. In such a way, the metastatic potential of
the melanoma cells would not necessarily be enhanced, but
instead, their establishment (and detection) at distal sites
may be improved. This is an intriguing possibility that we
cannot formerly exclude and may also contribute towards our
observations. However, the characterization in vitro of both
B16F10 and A375 melanomas shows that CAV1 expression
enhances migration and Rac1 activation [4,19] as well as
invasion in a matrigel assay (data not shown). These findings
are consistent with our interpretation of the current results
that the intrinsic metastatic potential of melanoma cells is
increased by the presence of CAV1 as reported here.
In patients, CAV1 presence in tumours often correlates with
a poor prognosis [18–22]. Our results analysing human
melanocytes and different stages of melanoma progression
suggest that CAV1 expression is linked to increased
metastatic potential [7] and follows a pattern similar to that
reported previously for prostate cancer [23]. In normal
prostate tissue, CAV1 has not been detected, but expression
increases upon tumour formation in mouse models and
human patients [24–27], and CAV1 presence promotes
metastasis of prostate cancer cells through an autocrine/
paracrine mechanism [23,28]. Moreover, levels of exosomes
carrying CAV1 were significantly elevated in patients
compared with healthy controls [6]. In addition, secreted
CAV1 detected in serum from patients with prostate cancer
is now being considered as a novel target for treatment.
Indeed, injection of anti-CAV1 antibodies reduced experi-
mental lung metastasis in a mouse model of prostate
cancer [23]. It is intriguing to speculate that CAV1
expression may not only follow a pattern similar to that
described for prostate cancer but also promotes metastasis
by similar mechanisms. However, more research is required
to substantiate such possibilities.
Intravenous injection of tumour cells into the tail vein
of animals is a frequently used approach to evaluate
metastasis. Here, two models were used to evaluate how
CAV1 expression affects melanoma behaviours in vivo.
Although a common experimental approach, intravenous
injection does not faithfully recapitulate all events associated
with tumour metastasis. In human patients, surgical
resection remains one of the most effective treatments for
melanomas, and yet, success is very much determined by
whether metastasis occurs or not. Thus, we reasoned that it
would be most appropriate to evaluate additionally the
consequences of CAV1 expression in melanoma in a clinically
more relevant setting for metastasis, akin to the situation in
human patients, where subcutaneous tumours are surgically
removed. To this end, B16F10 tumours were allowed to grow
to a defined size and then surgically excised. After another
14 days, mice were killed and both subcutaneous tumour
formation at the original site and metastasis to the lung (and
elsewhere) were quantified. Here, two points are worth
noting. First, a qualified human surgeon (J.G.F.) conducted
these procedures following the same criteria used in humans.
Second, the C57BL6 mice used here had a fully functional
immune system. Thus, the results obtained in this manner
are likely to bear greater relevance to the situation in human
patients undergoing surgery. Under these experimental
circumstances, CAV1 presence was identified as a post-
surgery risk factor because expression in B16F10 melanomas
favoured metastasis to the lung after intervention.
The data presented here are in agreement with a report by
Felicetti et al. [7] indicating that CAV1 expression is
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associated with increased metastatic potential in different
human melanoma cell lines. However, a report by Trimmer
and colleagues suggested that CAV1 expression is reduced in
human metastatic melanoma cell lines and blocks metastasis
of malignant melanomas. In particular, CAV1 overexpression
in B16F10 cells was shown to increase proliferation but
reduce lung metastasis [8]. The reason for this difference,
particularly also with respect to our results shown here, is not
clear. However, in a previous study from our group, we
validated the notion that CAV1 expression is upregulated in
metastatic melanomas in a meta-analysis including hundreds
of different lines, showing that CAV1 mRNA levels are
increased in invasive compared with proliferative melanoma
lines [4]. Moreover, we corroborated our previous findings
with B16F10 cells in two different ways. On the one hand,
using protocols similar to those we previously described for
B16F10 cells, we show here for human melanoma cells that
CAV1 functions as a tumour suppressor upon subcutaneous
injection of melanoma cells, but favours metastasis to the
lung when injected intravenously. In addition, we developed
a new experimental protocol similar to that used by surgeons
in patients and found again that CAV1 expression in mouse
and human melanomas favours metastatic dissemination
after tumour surgery.
Conclusion
In summary, enhanced CAV1 expression in human
melanomas is linked here to augmented metastatic
potential. Moreover, CAV1 is identified as a negative
prognostic marker in melanoma patients undergoing
surgery because the presence of the protein at levels
comparable to those observed in the human melanoma
samples is directly associated in our preclinical surgery
models with increased lung metastasis.
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